A Dendreon Options Trade: Hedging ASCO 2012 Data Releases

By Smith On Stocks: Investment Conclusion

By Osman Gulseven:Investing in Dendreon (DNDN) is a risky business. The company currently relies only on one product: Provenge. While Dendreon has a few drug candidates in the pipeline, the timeline for FDA submission is uncertain.

By William Meyers: After finally getting FDA approval for prostate cancer therapy Provenge in May 2010, Dendreon's management thought their main problem would be setting up enough manufacturing capability to meet patient demand. Instead, and largely due to the FDA's unconscionable approval delay, by the time Provenge was available prostate cancer competing therapies were coming to market, from companies with larger and more experienced sales forces.

By ValueMax:Dendreon (DNDN) currently has one FDA approved drug on the market. Provenge is a prostate cancer vaccine treatment manufactured by Dendreon and so far its run in the market has been a disappointing one. The fact that Provenge costs $93,000 for treatment over the course of one month has completely stifled sales.

Michael Shulman submits: I clearly ruffled some feathers with my write-up of Dendreon (DNDN), mostly those of Dendreon bulls, many of them traders who know little if anything about the company. They accused me of everything from being a moron to a child molester because I said an approval for Provenge was not a slam dunk. So let me make myself very clear.

By Saul Kerpelman: Dendreon Corporation (DNDN) held a very interesting conference call yesterday evening to outline its restructuring to deal with the slower than predicted launch of its newly approved cancer treatment, Provenge for late-stage prostate cancer.

VFC submits: It was an historic day for the future of cancer treatment when the FDA approved Dendreon's (DNDN) Provenge for the treatment of prostate cancer just over one year ago. It opened the doors to a new age in the treatment of cancer, and shareholders delighted alongside victims of prostate cancer -- patients who had long been looking for an alternative to the harsh side effects of chemotherapy and radiation treatments.

By Ian Bezek:Dendreon (DNDN) shares have been absolutely decimated in the past month, with shares falling almost 75% from $40 at this point last month to $10.37 as of this writing. The majority of the loss came as the market digested the company's latest disastrous earnings report, which included a huge revenue miss and a removal of the company's previous revenue guidance.